31 results about "Allergy vaccine" patented technology

The present invention relates to allergy vaccines and methods of treating and / or preventing asthma, and allergic conditions. The invention is based on the discovery that inhibiting the ligand / receptor interactions involving, e.g., IgE, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, interferon-alpha, histamine, leukotriene, and their respective receptors, inhibits production of IgE thereby treating or preventing such diseases or conditions. Competitive inhibition of such receptor / ligand interactions is accomplished by immunizing a human or veterinary patient with the interleukin, interferon-alpha, histamine, leukotriene, their receptors, in any combination. Also, the invention relates to inhibiting receptor / ligand interactions involved in IgE production by competitively inhibiting such interactions by administering antibodies to the ligands, receptors, or both, as well as by administering analogs of the receptors (e.g., soluble receptors not associated with a cell).

Use of a composition comprising an allergen and an adjuvant selected from the group consisting of oxygen-containing metal salts for the manufacture of a liquid formulation for preventing or treating allergy in a subject by oromucosal administration, and a method of preventing and treating allergy in a subject by oromucosal administration of the said liquid formulation.

The present invention relates to a method of preventive treatment of allergy to an allergen in a subject comprising administering an allergy vaccine containing the allergen as active substance to a mucosal surface of the subject, a) wherein the subject to be treated is sensitised so as to exhibit an IgE response specific to the allergen, b) wherein the subject to be treated is free of clinical symptoms of the allergy associated with the allergen, and c) wherein the preventive treatment is aimed at preventing or reducing subsequent clinical symptoms of the allergy associated with the allergen.

A method is disclosed wherein an antigenic B-cell epitope is discovered by in vitro transcription and translation of pre-determined sequence on thermostable protein scaffolds detected by antibodies to a native protein. Immune reactivities of IgE B-cell epitopes from pre-determined IgE sequences from the constant region, engaged in binding to high affinity IgE Fc receptors, placed in a loop of green fluorescent protein (GFP) were shown immuno-reactive with anti-IgE. Moreover, the antigenic B-cell epitope can be further optimized by molecular evolution, selected by conformer antibody and receptor on solid phase via ribosome display. Alternatively, a random aptameric antigenic sequence inserted into a loop of the protein scaffold, mimicking a pre-determined sequence of a native protein, can be selected by solid phase conformer antibody and receptor via ribosome display. High affinity binding of B-cell epitopes selected from the random aptameric library with antibodies to native pre-determined B-cell epitope of a native protein can be optimized by molecular evolution with error-prone RT-PCR by ribosome display.

The present invention relates to the field of immunology, immuno-allergy and especially the use of adjuvants or carriers for modulating the immune response to allergens. The object of the present invention is to prepare a therapeutic or prophylactic pharmaceutical preparation using bacterial proteoliposomes which, when applied to allergic individuals, is able to switch Th2 and IgE dependent allergic responses into protective Th1 responses ; and it also prevents the emergence and development of allergies in still non-allergic individuals. The vaccine composition comprises proteoliposomes from Gram-negative bacteria coupled to an allergen and optionally other adjuvants or antigens. The present invention also relates to methods of preparing the inventive vaccine composition and a two-dose immunization regimen with said vaccine composition.

The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease. The vaccine composition contains: an immunomodulator which is a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt of the lipopolysaccharide; and at least one allergen.

The invention provides an adjuvant for a desensitization vaccine, which includes an immune tolerance-inducing component, and the immune tolerance-inducing component is an anti-inflammatory compound. The present invention also provides a novel desensitizing vaccine using an anti-inflammatory compound as an adjuvant. In the present invention, the anti-inflammatory compound is used as an adjuvant and co-injected with the allergen to prevent the inflammation of the allergic vaccine at the site; the anti-inflammatory compound has the effect of inhibiting the maturation of antigen-presenting cells, and the anti-inflammatory compound directly acts on the antigen-presenting cells, inhibiting They become mature cells during antigen uptake and presentation; anti-inflammatory compounds achieve long-lasting treatment of allergies by rapidly inducing the generation of Treg cells. The desensitization vaccine provided by the invention can realize rapid, long-acting and effective treatment of allergic symptoms from the mechanism of sensitization.

The present invention relates to polypeptides comprising at least 3 peptide fragments consisting of 10 to 50 contiguous amino acid residues of at least 1 wild-type allergen fused to the Hepadnaviridae family N- and C-termini of viral surface polypeptides or at least 1 fragment fused to said surface polypeptides.

The invention provides methods and materials related to vaccines against self polypeptides. For example, the invention provides compositions containing chimeric IgE polypeptides and adjuvants.